Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
What adjuvant therapy would you recommend for a postmenopausal female with a dedifferentiated endometrial cancer, extensive LVI but negative nodes, MSI-high (somatic) and >50% myometrial invasion?
Related Questions
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
For a borderline ovarian tumor that has been resected with BSO and hysterectomy, would you consider endocrine therapy if found to be ER-positive?
In a patient with stage IVB HER2 3+ high-grade serous endometrial cancer who had disease confined to a polyp and "microscopic" omental metastases, how long would you continue maintenance trastuzumab after chemotherapy?
Would you offer systemic chemotherapy to a patient with at least 2023 FIGO stage IC high grade serous (p53-mut) endometrial cancer with extensive LVI for whom nodal assessment was not done?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
What is your experience with in vitro chemosensitivity testing?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
